Slide 1: Q3'24 Earnings Presentation
Enabling discovery, safety and production of tomorrow’s therapeutics NASDAQ: HBIO Q3’24 Earnings Presentation Jim Green, Chairman, President & CEO Jennifer Cote, CFO & Treasurer November 7, 2024 Updated November 21, 2024
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Forward-Looking Statements This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified b
Slide 3: CEO Summary: Q3'24 Highlights
CEO Summary: Q3’24 Highlights Stay the course, stay lean and remain focused on product commercializations for new revenue streams Income Statement Components ($ in millions except percentages) Q3 2024 Q3 2023 Revenue 22.0 25.4 Gross Margin 12.8 14.7 % of Revenue 58.1% 58.1% Operating Loss (1.9) (0.9
Slide 4: Q3'24 Revenue by Geography – Updated
Q3’24 Revenue by Geography – Updated** Fx Adjustment (in $M) Q1'24 Q2'24 Q3'24 Q3'23 As Reported CMT $ 10.9 $ 11.7 $ 11.8 $ 11.7 1.0% Pre-Clinical $ 13.5 $ 11.4 $ 10.1 $ 13.7 -26.2% Currency* $ 0.1 $ (0.0) $ 0.1 0.3% Total $ 24.5 $ 23.1 $ 22.0 $ 25.4 -13.4% Americas EMEA APAC • Overall: Down 15.9% y
Slide 5: Q3'24 Financial Metrics (GAAP except where noted)
Q3’24 Financial Metrics (GAAP except where noted) $ Million except REVENUE ADJUSTED EBITDA* per share data GROSS MARGIN $2.2 $1.3 (LOSS) EARNINGS PER SHARE CASH FLOW FROM OPERATIONS NET DEBT* GAAP Adjusted* Q3’24 Q3’23 Q3’24 Q3’23 Q3’24 Q3’23 * Non-GAAP measure, reconciliations to GAAP financial mea
Slide 6: 2024 New Product Introductions: Supports Long Term Growth Targets
2024 New Product Introductions: Supports Long Term Growth Targets Growth Category Product Line Application Customers Production Status Commercial Status • CROs • Q3: Soho Production • SoHo Shared • Safety • Began first SoHo commercial shipments Shipments Housing Telemetry Pharmacology Base • Biophar
Slide 7: Outlook
7 Outlook 7
Slide 8: 2024 Outlook
2024 Outlook For FY2024, we now expect: ▪ Q4 revenues of ~ $23-26M, full year 2024 revenue of ~$93-$96M ▪ Expanding adoption of our new telemetry and neuro behavior, bioproduction and the emerging MeshMEA organoid systems to support sequential growth. ▪ Q4 and full year Gross Margins in the 59-60% r
Slide 9: Appendix
9 Appendix 9
Slide 10: Reconciliation to GAAP P&L
Reconciliation to GAAP P&L (1) Other operating expenses for the three months ended September 30, 2024 includes $0.2 million of restructuring-related charges. Other operating expenses for the nine months ended September 30, 2024 includes a $0.5 million commission fee paid in connection with the recei
Slide 11: 1200
1200